-->
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definition
1.1.1.1. Product Segment
1.1.1.2. Application Segment
1.1.1.3. End Use Segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objective
1.4.1. Objective 1
1.4.2. Objective 2
1.4.3. Objective 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing focus on glycomics and proteomics research
3.2.1.2. Rising R & D investments by pharmaceutical and biotechnology companies
3.2.1.3. Technological advancements
3.2.1.4. Increasing focus on developing alternative to animal testing
3.2.2. Market Restraint Analysis
3.2.2.1. High cost of glycomics instruments
3.2.2.2. Stringent government policies and regulations
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Product Business Analysis
4.1. Glycomics Market: Product Movement Analysis
4.2. Enzymes
4.2.1. Enzymes Market, (2025-2033)
4.2.2. Glycosidases
4.2.2.1. Glycosidases Market, (2025-2033)
4.2.3. Glycosyltransferases
4.2.3.1. Glycosyltransferases Market, (2025-2033)
4.2.4. Neuraminidases
4.2.4.1. Neuraminidases Market, (2025-2033)
4.2.5. Sialyltransferases
4.2.5.1. Sialyltransferases Market, (2025-2033)
4.2.6. Others
4.2.6.1. Others Market, (2025-2033)
4.3. Kits
4.3.1. Kits Market, (2025-2033)
4.3.2. Glycan labeling kits
4.3.2.1. Glycan labeling kits Market, (2025-2033)
4.3.3. Glycan purification kits
4.3.3.1. Glycan purification kits Market, (2025-2033)
4.3.4. Glycan release kits
4.3.4.1. Glycan release kits Market, (2025-2033)
4.3.5. Other glycomics kits
4.3.5.1. Other glycomics kits Market, (2025-2033)
4.4. Reagents
4.4.1. Reagents Market, (2025-2033)
4.4.2. Glycoproteins
4.4.2.1. Glycoproteins Market, (2025-2033)
4.4.3. Monosaccharides
4.4.3.1. Monosaccharides Market, (2025-2033)
4.4.4. Oligosaccharides
4.4.4.1. Oligosaccharides Market, (2025-2033)
4.4.5. Other reagents
4.4.5.1. Other reagents Market, (2025-2033)
4.5. Instruments
4.5.1. Instruments Market, (2025-2033)
4.5.2. Mass spectrometers
4.5.2.1. Mass spectrometers Market, (2025-2033)
4.5.3. HPLC
4.5.3.1. HPLC Market, (2025-2033)
4.5.4. MALDI-TOF
4.5.4.1. MALDI-TOF Market, (2025-2033)
4.5.5. Array systems
4.5.5.1. Array systems Market, (2025-2033)
4.5.6. Others
4.5.6.1. Others Market, (2025-2033)
Chapter 5. Application Business Analysis
5.1. Glycomics Market: Application Movement Analysis
5.2. Drug Discovery & Development
5.2.1. Drug Discovery & Development Market, (2025-2033)
5.3. Diagnostics
5.3.1. Diagnostics Market, (2025-2033)
5.4. Others
5.4.1. Others Market, (2025-2033)
Chapter 6. End Use Business Analysis
6.1. Glycomics Market: End Use Movement Analysis
6.2. Academic & Research Institutes
6.2.1. Pharmaceutical & Biotechnology Companies Market, (2025-2033)
6.3. Pharmaceutical & Biotechnology Companies
6.3.1. Academic & Research Institutes Market, (2025-2033)
6.4. Biopharmaceutical Companies
6.4.1. Biopharmaceutical Companies Market, (2025-2033)
6.5. CROs
6.5.1. CROs Market, (2025-2033)
Chapter 7. Regional Business Analysis
7.1. Glycomics Market Share By Region, (2025-2033)
7.2. North America
7.2.1. North America Glycomics Market, (2025-2033)
7.2.2. U.S.
7.2.2.1. Key Country Dynamics
7.2.2.2. Target Disease Prevalence
7.2.2.3. Competitive Scenario
7.2.2.4. U.S. Glycomics Market, (2025-2033)
7.2.3. Canada
7.2.3.1. Key Country Dynamics
7.2.3.2. Target Disease Prevalence
7.2.3.3. Competitive Scenario
7.2.3.4. Canada Glycomics Market, (2025-2033)
7.3. Europe
7.3.1. Europe Glycomics Market, (2025-2033)
7.3.2. UK
7.3.2.1. Key Country Dynamics
7.3.2.2. Target Disease Prevalence
7.3.2.3. Competitive Scenario
7.3.2.4. UK Glycomics Market, (2025-2033)
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Target Disease Prevalence
7.3.3.3. Competitive Scenario
7.3.3.4. Germany Glycomics Market, (2025-2033)
7.3.4. France
7.3.4.1. Key Country Dynamics
7.3.4.2. Target Disease Prevalence
7.3.4.3. Competitive Scenario
7.3.4.4. France Glycomics Market, (2025-2033)
7.3.5. Italy
7.3.5.1. Key Country Dynamics
7.3.5.2. Target Disease Prevalence
7.3.5.3. Competitive Scenario
7.3.5.4. Italy Glycomics Market, (2025-2033)
7.3.6. Spain
7.3.6.1. Key Country Dynamics
7.3.6.2. Target Disease Prevalence
7.3.6.3. Competitive Scenario
7.3.6.4. Spain Glycomics Market, (2025-2033)
7.3.7. Denmark
7.3.7.1. Key Country Dynamics
7.3.7.2. Target Disease Prevalence
7.3.7.3. Competitive Scenario
7.3.7.4. Denmark Glycomics Market, (2025-2033)
7.3.8. Sweden
7.3.8.1. Key Country Dynamics
7.3.8.2. Target Disease Prevalence
7.3.8.3. Competitive Scenario
7.3.8.4. Sweden Glycomics Market, (2025-2033)
7.3.9. Norway
7.3.9.1. Key Country Dynamics
7.3.9.2. Target Disease Prevalence
7.3.9.3. Competitive Scenario
7.3.9.4. Norway Glycomics Market, (2025-2033)
7.4. Asia Pacific
7.4.1. Asia Pacific Glycomics Market, (2025-2033)
7.4.2. Japan
7.4.2.1. Key Country Dynamics
7.4.2.2. Target Disease Prevalence
7.4.2.3. Competitive Scenario
7.4.2.4. Japan Glycomics Market, (2025-2033)
7.4.3. China
7.4.3.1. Key Country Dynamics
7.4.3.2. Target Disease Prevalence
7.4.3.3. Competitive Scenario
7.4.3.4. China Glycomics Market, (2025-2033)
7.4.4. India
7.4.4.1. Key Country Dynamics
7.4.4.2. Target Disease Prevalence
7.4.4.3. Competitive Scenario
7.4.4.4. India Glycomics Market, (2025-2033)
7.4.5. Australia
7.4.5.1. Key Country Dynamics
7.4.5.2. Target Disease Prevalence
7.4.5.3. Competitive Scenario
7.4.5.4. Australia Glycomics Market, (2025-2033)
7.4.6. Thailand
7.4.6.1. Key Country Dynamics
7.4.6.2. Target Disease Prevalence
7.4.6.3. Competitive Scenario
7.4.6.4. Thailand Glycomics Market, (2025-2033)
7.4.7. South Korea
7.4.7.1. Key Country Dynamics
7.4.7.2. Target Disease Prevalence
7.4.7.3. Competitive Scenario
7.4.7.4. South Korea Glycomics Market, (2025-2033)
7.5. Latin America
7.5.1. Latin America Glycomics Market, (2025-2033)
7.5.2. Brazil
7.5.2.1. Key Country Dynamics
7.5.2.2. Target Disease Prevalence
7.5.2.3. Competitive Scenario
7.5.2.4. Brazil Glycomics Market, (2025-2033)
7.5.3. Mexico
7.5.3.1. Key Country Dynamics
7.5.3.2. Target Disease Prevalence
7.5.3.3. Competitive Scenario
7.5.3.4. Mexico Glycomics Market, (2025-2033)
7.5.4. Argentina
7.5.4.1. Key Country Dynamics
7.5.4.2. Target Disease Prevalence
7.5.4.3. Competitive Scenario
7.5.4.4. Argentina Glycomics Market, (2025-2033)
7.6. MEA
7.6.1. MEA Glycomics Market, (2025-2033)
7.6.2. South Africa
7.6.2.1. Key Country Dynamics
7.6.2.2. Target Disease Prevalence
7.6.2.3. Competitive Scenario
7.6.2.4. South Africa Glycomics Market, (2025-2033)
7.6.3. Saudi Arabia
7.6.3.1. Key Country Dynamics
7.6.3.2. Target Disease Prevalence
7.6.3.3. Competitive Scenario
7.6.3.4. Saudi Arabia Glycomics Market, (2025-2033)
7.6.4. UAE
7.6.4.1. Key Country Dynamics
7.6.4.2. Target Disease Prevalence
7.6.4.3. Competitive Scenario
7.6.4.4. UAE Glycomics Market, (2025-2033)
7.6.5. Kuwait
7.6.5.1. Key Country Dynamics
7.6.5.2. Target Disease Prevalence
7.6.5.3. Competitive Scenario
7.6.5.4. Kuwait Glycomics Market, (2025-2033)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Market Share/Position Analysis, 2025
8.4. Company Profiles/Listing
8.4.1. Thermo Fisher Scientific, Inc
8.4.1.1. Overview
8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. Merck KGaA
8.4.2.1. Overview
8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Agilent Technologies Inc.
8.4.3.1. Overview
8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. Bruker
8.4.4.1. Overview
8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. New England Biolabs
8.4.5.1. Overview
8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. Shimadzu Corporation
8.4.6.1. Overview
8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. Waters Corporation
8.4.7.1. Overview
8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. Takara Bio Inc
8.4.8.1. Overview
8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. Asparia Glycomics
8.4.9.1. Overview
8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. RayBiotech Life, Inc.
8.4.10.1. Overview
8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives
著作権 ©2022 無断複写・転載を禁じます